Abstract
Background: Heterogeneous mechanisms may contribute to the occurrence of mitral annular calcification (MAC), however, little is known about the sex differences in MAC and the clinical implications of these differences. This study aimed to investigate clinical and imaging differences of MAC according to sex.
Methods: In total, 537 patients (221 men) with MAC were identified by transthoracic echocardiography at a single center from January 2012 to June 2016. Moderate-to-severe MAC was defined as calcification extent ≥120° of the mitral annulus. Significant functional mitral stenosis (MS) was defined as a transmitral mean diastolic pressure gradient ≥5 mmHg.
Results: Women more frequently had moderate-to-severe MAC and concomitant mitral regurgitation than men; however, significant functional MS was comparable between sexes. In the logistic regression analysis, old age, uncontrolled hypertension, end-stage renal disease (ESRD), and obstructive hypertrophic cardiomyopathy were significantly associated with moderate-to-severe MAC in women, whereas ESRD and moderate-to-severe aortic stenosis were in men. In the Cox regression analysis, significant functional MS was associated with all-cause death in both sexes, although an independent association was found in only women.
Conclusion: Women had more extended MAC than men. Significant functional MS was independently associated with unfavorable clinical outcomes in patients with MAC, which was more pronounced in women than in men.
Introduction
Mitral annular calcification (MAC) is a chronic degenerative process in the fibrous base of the mitral valve (1). Early studies highlighted that MAC is associated with cardiovascular risk factors and is independently related to the occurrence of cardiovascular diseases such as stroke, coronary artery disease, and atrial fibrillation (2–4). These associations may explain why MAC is a progressive disease with features similar to atherosclerosis (5, 6). However, previous studies have shown that MAC is more frequent in women than in men, which cannot be explicated by the atherosclerosis paradigm (7, 8). This is probably related to other risk factors for MAC that differ according to sex, such as abnormal calcium-phosphate product or post-menopausal osteoporosis (9, 10). Therefore, it is assumed that there are differences according to sex regarding the mechanism, characteristics, and risk factors of MAC. Over the past decades, some studies have reported a sex difference in subjects with MAC. One study showed that larger calcium deposits more frequently occur in women than in men, based on a pathological evaluation of patients with MAC (9). Another study demonstrated that calcification activity in MAC was closely associated with female sex (11). Regardless of these accumulating results, the sex differences in the clinical and echocardiographic characteristics of subjects with MAC remain ambiguous. Thus, we aimed to investigate clinical and imaging differences of MAC according to sex. Additionally, we aimed to study sex-specific differences in the severity and prognosis of MAC.
Materials and Methods
Study Design and Population
In total, 537 patients with MAC were retrospectively identified by transthoracic echocardiography in a single tertiary institution (Yonsei University Cardiovascular Hospital, Seoul, Republic of Korea) from January 2012 to June 2016. Patients who had rheumatic mitral stenosis (MS), congenital mitral valve disease, an inadequate quality of echocardiographic data for assessment of MAC, and undergone mitral valve surgery were excluded. The study was approved by the local institutional review board (IRB no. 4-2017-0822) and complied with the Declaration of Helsinki. As this registry-based retrospective study and the data were analyzed anonymously, informed consent was not required from the study subjects.
Echocardiography
Standard two-dimensional and Doppler echocardiography measurements were performed following the American Society of Echocardiography guidelines (12). MAC was defined as a thick and echo-dense area of the mitral annulus, occasionally extending to the mitral valve leaflets, as described in previous studies (3, 13). Comprehensive echocardiography reviews were performed to define functional and structural characteristics of the left ventricle and MAC (thickness, location, extent, and functional MS). To determine which annulus was mainly distributed with calcium, MAC was evaluated by parasternal long-axis, parasternal short-axis, apical 4-chamber, 3-chamber, and 2-chamber views. Severity of MAC was qualitatively determined in the parasternal short-axis view at the level of the mitral annulus as mild (focal, limited increase in echodensity within 120° of the mitral annulus), moderate (marked echodensity within 120–180° of the mitral annulus), or severe (marked echodensity at >180° of the mitral annulus) (14). MAC thickness was measured from the leading anterior to the trailing posterior edge at its greatest width. Figures 1A–C shows representative cases of mild, moderate, and severe MAC, respectively. The estimation of the diastolic pressure gradient was derived from the transmitral velocity flow curve using continuous wave Doppler echocardiography. Significant functional MS was defined as a transmitral mean diastolic pressure gradient ≥5 mmHg (15). In patients with atrial fibrillation, the mean gradient was calculated as the average of five cycles with the least variation of R–R intervals as close as possible to the normal heart rate.
Figure 1
Representative cases of mild (A), moderate (B), and severe (C) mitral annular calcification.
Clinical Data
Demographic, anthropometric, and laboratory data at the time of echocardiography were collected from patients' electrical medical records. All-cause death data were also collected from the electrical medical records. Diagnosis of hypertrophic cardiomyopathy (HCM) was made clinical criteria; maximal end-diastolic wall thickness of ≥15 mm anywhere in the left ventricle (LV), in the absence of another cause of hypertrophy. Uncontrolled hypertension was defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg in patients taking anti-hypertensive treatment. The severities of mitral regurgitation (MR) and aortic stenosis (AS) were determined according to the current guideline (16).
Statistical Analysis
All continuous data are presented as mean ± standard deviation, and categorical data are expressed as number and percentage for each group. Univariable and multivariable linear regression analyses were performed to assess which factors were independent determinants of moderate to severe MAC. Univariate outcomes with a p < 0.1 were selected for inclusion in multivariable analysis. This linear regression analysis was performed separately in patients without end-stage renal disease (ESRD). Kaplan–Meier survival analysis was performed to evaluate the association of significant MS and all-cause death. Univariate and multivariate Cox regression analyses were performed to determine the risk factors of all-cause death. All tests were two-sided, and statistical significance was defined as p < 0.05. All statistical analyses were performed using R statistical software (version 3.6.0; R Foundation for Statistical Computing, Vienna, Austria).
Results
Baseline and Echocardiographic Characteristics
Among 537 patients, 316 were women, and the mean age was 74.7 ± 10.5 years. Women were significantly older and had a greater body mass index (BMI), higher systolic blood pressure, and higher pulse pressure than men. The prevalences of hypertension, diabetes, dyslipidemia, coronary artery disease, and AS were comparable between the sexes. Current smoking status, ESRD, and moderate-to-severe AS were more frequent in men than in women; however, HCM was more frequent in women than in men, as shown in Table 1. Women more frequently had MAC limited to the posterior annulus while combined anterior and posterior annular calcification was more frequently found in men. There were no differences in MAC thickness and significant MS between the sexes. MR was more frequently observed in women than in men; however, there was no significant difference in the prevalence of moderate or severe MR between the sexes. Women with MAC showed smaller LV dimensions, a lower e′ velocity, and a higher E/e′ than men with MAC (Table 2).
Table 1
| Men (n = 221) | Women (n = 316) | P-value | |
|---|---|---|---|
| Age, years | 73 ± 11 | 76 ± 10 | 0.001 |
| 80 ≥ years old, n (%) | 60 (27) | 125 (40) | 0.004 |
| Body mass index, kg/m2 | 23.4 ± 3.0 | 24.4 ± 4.6 | 0.002 |
| Systolic BP, mmHg | 131 ± 22 | 137 ± 22 | 0.001 |
| Diastolic BP, mmHg | 71 ± 13 | 73 ± 13 | 0.181 |
| Pulse pressure, mmHg | 59 ± 19 | 64 ± 19 | 0.002 |
| Uncontrolled hypertension, n (%) | 81 (37) | 145 (46) | 0.225 |
| Diabetes Mellitus, n (%) | 75 (34) | 99 (31) | 0.525 |
| Dyslipidemia, n (%) | 110 (50) | 163 (52) | 0.680 |
| Smoking, n (%) | 112 (52) | 21 (7) | <0.001 |
| Coronary artery disease, n (%) | 93 (42) | 126 (40) | 0.608 |
| Atrial fibrillation, n (%) | 48 (22) | 69 (22) | >0.999 |
| ESRD, n (%) | 63 (29) | 48 (15) | <0.001 |
| Obstructive HCM, n (%) | 2 (1) | 15 (5) | 0.024 |
| Moderate or severe AS, n (%) | 103 (47) | 99 (31) | <0.001 |
| Mitral valve prolapse, n (%) | 2 (0.9) | 3 (0.9) | >0.999 |
| Osteoporosis, n (%) | 15 (7) | 73 (23) | <0.001 |
Baseline characteristics.
BP, blood pressure; ESRD, end-stage renal disease; HCM, hypertrophic cardiomyopathy; AS, aortic stenosis.
Table 2
| Men (n = 221) | Women (n = 316) | P-value | |
|---|---|---|---|
| MAC characteristics | |||
| Max thickness, cm | 0.53 ± 0.28 | 0.52 ± 0.23 | 0.743 |
| Site, n(%) | |||
| Anterior MAC | 2 (1) | 5 (2) | 0.768 |
| Posterior MAC | 166 (75) | 264 (84) | 0.022 |
| Bilateral MAC | 53 (24) | 47 (15) | 0.011 |
| Extents, n (%) | |||
| Mild (<120°) | 155 (70) | 167 (53) | <0.001 |
| Moderate to severe (≥120°) | 66 (30) | 149 (47) | <0.001 |
| Significant mitral stenosis, n (%) | 23 (10) | 34 (11) | >0.999 |
| Mitral regurgitation, n (%) | 79 (36) | 152 (48) | 0.006 |
| No, n (%) | 142 (64) | 164 (52) | 0.006 |
| Mild, n (%) | 59 (27) | 111 (35) | 0.049 |
| Moderate, n (%) | 14 (6) | 35 (11) | 0.084 |
| Severe, n (%) | 6 (3) | 6 (2) | 0.739 |
| Chamber characteristics | |||
| LVEDD, mm | 51.3 ± 7.3 | 47.5 ± 6.4 | <0.001 |
| LVESD, mm | 35.6 ± 8.6 | 31.8 ± 7.2 | <0.001 |
| LV mass index, g/m2 | 132.3 ± 46.8 | 123.6 ± 35.7 | 0.017 |
| LA volume index, ml/m2 | 48.4 ± 18.7 | 49.2 ± 18.3 | 0.647 |
| E velocity, m/s | 0.91 ± 0.31 | 0.94 ± 0.31 | 0.234 |
| e′ velocity, cm/s | 4.6 ± 1.5 | 4.1 ± 1.4 | <0.001 |
| E/e′ | 21.4 ± 10.0 | 24.1 ± 9.4 | 0.003 |
Echocardiographic characteristics.
MAC, mitral annular calcification; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; LV, left ventricular; LA, left atrial; E, early diastolic mitral inflow; e′, early diastolic mitral tissue Doppler; E/e′, the ratio of early diastolic mitral inflow velocity to early diastolic mitral tissue Doppler velocity.
Factors Associated With Moderate to Severe Mitral Annular Calcification
In the multivariable logistic regression analysis, determinants of moderate-to-severe MAC were elderly age (≥80 years), female sex, ESRD, and obstructive HCM in the total study population. Only ESRD and moderate-to-severe AS were independently associated with moderate-to-severe MAC in men. On the contrary, elderly age, uncontrolled hypertension, ESRD, and obstructive HCM showed a significant relationship with moderate-to-severe MAC in women, as shown in Table 3. Similar associations were observed when excluding patients with ESRD (Supplementary Table 1).
Table 3
| Univariate | Multivariate | |||
|---|---|---|---|---|
| OR (95% CI) | P-value | OR (95% CI) | P-value | |
| Total (n=537) | ||||
| Age | 1.00 (0.99–1.01) | 0.308 | ||
| 80 ≥ years old | 1.10 (1.01–1.20) | 0.027 | 1.12 (1.02–1.22) | 0.014 |
| Female sex | 1.19 (1.09–1.29) | <0.001 | 1.20 (1.10–1.30) | <0.001 |
| Body mass index | 1.00 (0.99–1.01) | 0.491 | ||
| Current smoking | 0.98 (0.81–1.19) | 0.867 | ||
| Uncontrolled hypertension | 1.07 (0.98–1.16) | 0.129 | ||
| Diabetes mellitus | 0.95 (0.87–1.04) | 0.287 | ||
| Dyslipidemia | 0.93 (0.85–1.01) | 0.070 | 0.93 (0.86–1.01) | 0.073 |
| Coronary artery disease | 0.99 (0.91–1.07) | 0.764 | ||
| ESRD | 1.14 (1.03–1.26) | 0.012 | 1.22 (1.11–1.36) | <0.001 |
| HCM obstructive | 1.29 (1.02–1.63) | 0.035 | 1.27 (1.01–1.60) | 0.042 |
| AS (≥ moderate) | 0.99 (0.92–1.09) | 0.960 | ||
| Osteoporosis | 1.04 (0.93–1.16) | 0.511 | ||
| Men (n=221) | ||||
| Age | 0.99 (0.99–1.00) | 0.729 | ||
| 80 ≥ years old | 1.07 (0.94–1.23) | 0.311 | 1.08 (0.94–1.24) | 0.279 |
| Body mass index | 0.99 (0.97–1.01) | 0.220 | ||
| Smoking | 1.06 (0.94–1.20) | 0.366 | ||
| Uncontrolled hypertension | 0.94 (0.83–1.07) | 0.333 | ||
| Diabetes mellitus | 0.93 (0.82–1.06) | 0.294 | ||
| Dyslipidemia | 0.92 (0.81–1.03) | 0.155 | ||
| CAD | 1.04 (0.92–1.18) | 0.510 | ||
| ESRD | 1.17 (1.03–1.34) | 0.019 | 1.21 (1.06–1.38) | 0.005 |
| HCM obstructive | 0.74 (0.39–1.40) | 0.356 | ||
| AS (≥ moderate) | 1.16 (1.02–1.30) | 0.019 | 1.16 (1.03–1.31) | 0.014 |
| Osteoporosis | 0.90 (0.71–1.14) | 0.390 | ||
| Women (n=316) | ||||
| Age | 1.00 (0.99–1.01) | 0.371 | ||
| 80 ≥ years old | 1.08 (0.97–1.21) | 0.164 | 1.14 (1.02–1.27) | 0.026 |
| Body mass index | 1.01 (0.99–1.02) | 0.412 | ||
| Smoking | 0.87 (0.62–1.21) | 0.401 | ||
| Uncontrolled hypertension | 1.13 (1.01–1.26) | 0.029 | 1.12 (1.00–1.25) | 0.044 |
| Diabetes mellitus | 0.98 (0.87–1.10) | 0.684 | ||
| Dyslipidemia | 0.93 (0.83–1.04) | 0.188 | ||
| CAD | 0.96 (0.85–1.07) | 0.434 | ||
| ESRD | 1.20 (1.03–1.4) | 0.021 | 1.25 (1.07–1.45) | 0.006 |
| HCM obstructive | 1.32 (1.02–1.7) | 0.038 | 1.42 (1.10–1.83) | 0.008 |
| Moderate or severe AS | 0.93 (0.83–1.05) | 0.257 | ||
| Osteoporosis | 1.01 (0.89–1.15) | 0.877 | ||
Associating factors with moderate to severe MAC.
OR, odds ratio; ESRD, end stage renal disease; HCM, hypertrophic cardiomyopathy; AS, aortic stenosis.
Clinical Outcomes in Patients With Mitral Annular Calcification
During the follow-up period (median, 5.3 years; interquartile range: 4.6–6.6 years), 106 deaths occurred. Figures 2A,B present the Kaplan–Meier curves to show the association between significant functional MS and all-cause death in both sexes. Patients who had significant functional MS had a higher probability of all-cause death than patients without significant MS, both in women and in men.
Figure 2
Cumulative incidences of all-cause death in women (A) and men (B) estimated using the Kaplan–Meier method. MS, mitral stenosis.
In the univariate Cox regression analysis, female sex and lower BMI were associated with a lower risk of mortality. Diabetes mellitus, ESRD, and significant MS were related to a higher risk of mortality. In the multivariate Cox regression analysis, older age, male sex, the presence of ESRD, and the presence of significant MS were independently associated with all-cause death (Table 4). When analyzing the data separately by sex, a lower BMI, ESRD, history of stroke, and significant MS were associated with mortality in men. However, only ESRD remained as a significant determinant of all-cause death in the multivariate model. In contrast, older age, diabetes mellitus, ESRD, and significant MS were significantly associated with mortality in the multivariate Cox regression model in women (Table 4).
Table 4
| Univariate | Multivariate | |||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Total (n=537) | ||||
| Age | 1.00 (0.99–1.02) | 0.609 | ||
| Female Sex | 0.56 (0.38–0.82) | 0.003 | 0.65 (0.44–0.95) | 0.027 |
| BMI | 0.93 (0.88–0.98) | 0.004 | 0.95 (0.90–1.00) | 0.061 |
| Current smoking | 0.96 (0.39–2.36) | 0.933 | ||
| Uncontrolled hypertension | 0.91 (0.62–1.33) | 0.616 | ||
| Diabetes mellitus | 1.51 (1.02–2.22) | 0.038 | 1.38 (0.92–2.05) | 0.110 |
| Dyslipidemia | 1.20 (0.82–1.76) | 0.350 | ||
| Coronary artery disease | 1.12 (0.76–1.64) | 0.566 | ||
| ESRD | 2.96 (2.01–4.36) | <0.001 | 2.04 (1.33–3.11) | 0.001 |
| Atrial fibrillation | 1.23 (0.79–1.90) | 0.354 | ||
| History of stroke | 2.42 (1.30–4.52) | 0.006 | 1.98 (1.04–3.74) | 0.037 |
| Moderate to severe MAC | 1.02 (0.69–1.5) | 0.927 | ||
| Moderate to severe MR | 1.03 (0.57–1.88) | 0.921 | ||
| Significant mitral stenosis | 2.66 (1.67–4.22) | <0.001 | 2.05 (1.26–3.33) | 0.004 |
| HCM, obstructive | 0.56 (0.14–2.25) | 0.412 | ||
| Moderate or severe AS | 0.92 (0.62–1.37) | 0.685 | ||
| Osteoporosis | 1.00 (0.99–1.02) | 0.609 | ||
| Men (n=221) | ||||
| Age | 1.00 (0.98–1.02) | 0.937 | 1.02 (0.99–1.05) | 0.096 |
| BMI | 0.92 (0.85–1.01) | 0.066 | 0.95 (0.87–1.04) | 0.264 |
| Current smoking | 0.88 (0.32–2.44) | 0.813 | ||
| Uncontrolled hypertension | 0.89 (0.52–1.54) | 0.682 | ||
| Diabetes mellitus | 1.14 (0.66–1.94) | 0.645 | ||
| Dyslipidemia | 0.99 (0.59–1.67) | 0.981 | ||
| Coronary artery disease | 1.35 (0.81–2.28) | 0.252 | ||
| ESRD | 3.05 (1.81–5.13) | <0.001 | 3.11 (1.70–5.67) | <0.001 |
| Atrial fibrillation | 0.97 (0.51–1.83) | 0.925 | ||
| History of stroke | 2.46 (1.11–5.43) | 0.026 | 1.85 (0.80–4.28) | 0.149 |
| Moderate to severe MAC | 1.31 (0.76–2.25) | 0.336 | ||
| Moderate to severe MR | 0.55 (0.17–1.77) | 0.317 | ||
| Significant mitral stenosis | 2.12 (1.07–4.20) | 0.031 | 1.59 (0.76–3.30) | 0.218 |
| HCM, obstructive | 0.02 (0.01–9.99) | 0.997 | ||
| Moderate or severe AS | 1.04 (0.62–1.75) | 0.875 | ||
| Osteoporosis | 1.47 (0.59–3.69) | 0.408 | ||
| Women (n=316) | ||||
| Age | 1.02 (0.99–1.06) | 0.134 | 1.05 (1.01–1.08) | 0.006 |
| BMI | 0.95 (0.88–1.00) | 0.053 | 0.94 (0.88–1.01) | 0.080 |
| Current smoking | 0.69 (0.09–4.97) | 0.709 | ||
| Uncontrolled hypertension | 1.02 (0.58–1.79) | 0.943 | ||
| Diabetes mellitus | 1.98 (1.13–3.47) | 0.017 | 1.88 (1.05–3.37) | 0.033 |
| Dyslipidemia | 1.50 (0.86–2.67) | 0.166 | ||
| CAD | 0.86 (0.48–1.54) | 0.616 | ||
| ESRD | 2.35 (1.26–4.36) | 0.007 | 2.47 (1.22–5.02) | 0.012 |
| Atrial fibrillation | 1.57 (0.86–2.89) | 0.143 | ||
| History of stroke | 2.08 (0.75–5.79) | 0.160 | ||
| Moderate to severe MAC | 0.99 (0.56–1.73) | 0.965 | ||
| Moderate to severe MR | 1.61 (0.78–3.31) | 0.199 | ||
| Significant mitral stenosis | 3.39 (1.80–6.40) | <0.001 | 2.89 (1.51–5.54) | 0.001 |
| HCM obstructive | 0.84 (0.20–3.44) | 0.803 | ||
| Moderate or severe AS | 0.61 (0.31–1.19) | 0.148 | ||
| Osteoporosis | 1.51 (0.82–2.77) | 0.186 | ||
Associating factors with all-cause death in men and women.
HR, hazard ratio; BMI, body mass index; ESRD, end stage renal disease; MAC, mitral annular calcification; MR, mitral regurgitation; AS, aortic stenosis; HCM, hypertrophic cardiomyopathy.
Discussion
The main findings of the study were as follows: (1) Women had more extended MAC than men and had smaller LV dimensions, a lower e′ velocity, and a higher E/e′ than men; (2) older age, uncontrolled hypertension, ESRD, and obstructive HCM were associated with moderate-to-severe MAC in women, although only ESRD and moderate-to-severe AS were significantly associated with moderate-to-severe MAC in men; and (3) significant functional MS was independently associated with all-cause death, though this finding was only significant in women on multivariable analysis.
MAC is usually considered a benign condition where the incidence increases with age; it is often found incidentally via echocardiography or computed tomography. However, it has been revealed that MAC is independently associated with a higher risk of several cardiovascular diseases and mortality. In the Framingham Heart Study, MAC was related to an increased risk of cardiovascular disease and all-cause death (2). The northern Manhattan study, which was a multi-ethnic cohort study, reported that MAC was a strong and independent predictor of myocardial infarction and vascular death (3). Similarly, several cohort studies have shown that MAC is significantly associated with stoke (13, 17). Moreover, some characteristics of MAC had more association with stroke than conventional risk factors (4). Atrial fibrillation is also well-known to be associated with MAC in several studies (18–20). A post-hoc analysis from the Multi-Ethnic Study of Atherosclerosis (MESA) study showed that the accumulation of higher levels of MAC over time is associated with an increased risk for atrial fibrillation development and that important prognostic information regarding one's atrial fibrillation risk are conveyed by the presence and progression of MAC (18–20).
The risk factors of MAC are aging, atherosclerosis, conditions predisposing one to LV hypertrophy (e.g., hypertension, AS, or obstructive HCM), abnormal regulation of calcium-phosphorus products, and female sex (8). The reason for the association between women and MAC is explained by the loss of estrogen, which plays a role in atheroprotection (21, 22) and ectopic calcium deposits related to bone loss in post-menopausal women (23, 24). In addition to this explanation, the fact that women generally have a smaller heart and tend to develop greater hypertrophy in response to hypertension than men also may be reasons why MAC is more common and more severe in women than in men (25, 26). When stress on the mitral valve and annulus is increased due to various cardiac conditions, such as uncontrolled hypertension, AS, obstructive HCM, or mitral valve prolapse, calcific degeneration of the mitral valve can deteriorate gradually. This is associated with endothelial injury caused by mechanical stress, focal accumulation of oxidative stress, or a localized inflammatory process (8, 27). In our study, women had a smaller heart and worse diastolic function than men. Additionally, moderate-to-severe MAC was significantly associated with older age and uncontrolled hypertension only in women. Our results support that the mechanical force related to increased afterload on a relatively small ventricle may be important in the pathogenesis of MAC in women.
One interesting finding of our study is that the feature of MAC related to mortality was significant functional MS, but the extent of MAC was not. Early studies tended to focus on anatomical severity and its association with clinical outcomes. In the Framingham Heart Study, for each 1-mm increase in MAC thickness, the risk of incident all-cause death adjusted for relevant baseline risk factors increased by 9% (2). In the MESA study, MAC was a strong predictor for risk of cardiovascular events, and the risk was directly associated with anatomical MAC severity (3). Recently, MAC has been recognized as one of the important causes of MS. This kind of MS is called degenerative MS (DMS), and it can be progressive with an increase of calcium burden on the mitral valve (28, 29). Moreover, the prognosis of patients with DMS was poor; the 1 and 5-year survival rates were 78 and 47% in a retrospective single-center study (30). Bertrand et al. performed a retrospective study of echocardiography data from a large single institution to present the natural history of MAC. They showed the prognostic significance of the transmitral mean gradient for mortality in patients with MAC. Concomitant MR is associated with high mortality in only low gradient ranges (3–5 mmHg), indicating prognostic utility of the transmitral gradient in MAC regardless of MR severity (31). Our study also showed that only significant functional MS, defined as ≥5 mmHg of the transmitral pressure gradient, was independently associated with mortality. These discrepant results in each study were presumed to be due to different characteristics of study population. In the Framingham Heart Study and MESA study, clinical events were compared between participants with MAC and participants without MAC, whereas all patients in our study and in Bertrand et al.'s study had MAC. It is assumed that the relationship between the severity of MAC and prognosis was more emphasized when patients without MAC were included in the analysis.
Limitations
The current study has several limitations. First, this study was retrospective in design, which causes an inherent limitation. Second, we reviewed echocardiography data retrospectively and identified MAC in patients from a single tertiary institution. Therefore, there may have been selection bias toward more severe MAC and greater risk of mortality. Third, evaluation of MAC using echocardiography may have limitations, especially in a retrospective setting. Depending on the quality of echocardiography, evaluation may be limited, and it is difficult to completely distinguish the boundary between MAC and normal tissue. Moreover, the MAC in the anterior annulus is often not well-imaged on the parasternal short-axis view. Further research combining 3D echocardiography or computed tomography may offer further insights. Fourth, only all-cause death was counted in the clinical events because it is difficult to determine the cause of death retrospectively and the follow-up period was different for each patient. However, since death is the most reliable and accurate clinical event, we assumed that it is an appropriate clinical event to identify which factors are associated with poor prognosis.
Conclusions
There were sex differences in clinical and echocardiographic characteristics in patients with MAC. Women had more extended MAC than men. The mechanical force associated with increased afterload on a relatively small ventricle could be more dominant in the pathogenesis of MAC in women. Additionally, a significantly elevated transmitral pressure gradient was independently associated with all-cause death in patients with MAC, which was more pronounced in women than in men.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving human participants were reviewed and approved by Yonsei University Institutional Review Board. The need for informed consent was waived by the Local Ethics Committee of the Yonsei University.
Author contributions
JS: data analysis, data collection, and drafting of the manuscript. HJ, J-WH, and G-RH: data collection and revising it critically for important intellectual content. IC: revising it critically for important intellectual content. CS: conception and design of study, drafting of the manuscript, and revising it critically for important intellectual content. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer declared a past co-authorship with the several of the authors JS, HJ, IC, G-RH, J-WH, and CS to the handling editor.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2021.736040/full#supplementary-material
References
1.
NesticoPFDepaceNLMorganrothJKotlerMNRossJ. Mitral annular calcification: clinical, pathophysiology, and echocardiographic review. Am Heart J. (1984) 107:989–96. 10.1016/0002-8703(84)90840-8
2.
FoxCSVasanRSPariseHLevyDO'DonnellCJD'AgostinoRBet al. Mitral annular calcification predicts cardiovascular morbidity and mortality: the Framingham Heart Study. Circulation. (2003) 107:1492–6. 10.1161/01.CIR.0000058168.26163.BC
3.
KohsakaSJinZRundekTBoden-AlbalaBHommaSSaccoRLet al. Impact of mitral annular calcification on cardiovascular events in a multiethnic community: the Northern Manhattan Study. JACC Cardiovasc Imaging. (2008) 1:617–23. 10.1016/j.jcmg.2008.07.006
4.
KimDShimCYHongGRJeongHHaJW. Morphological and functional characteristics of mitral annular calcification and their relationship to stroke. PLoS One. (2020) 15:e0227753. 10.1371/journal.pone.0227753
5.
KanjanauthaiSNasirKKatzRRiveraJJTakasuJBlumenthalRSet al. Relationships of mitral annular calcification to cardiovascular risk factors: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. (2010) 213:558–62. 10.1016/j.atherosclerosis.2010.08.072
6.
RobertsWC. The senile cardiac calcification syndrome. Am J Cardiol. (1986) 58:572–4. 10.1016/0002-9149(86)90045-7
7.
BoonACheriexELodderJKesselsF. Cardiac valve calcification: characteristics of patients with calcification of the mitral annulus or aortic valve. Heart. (1997) 78:472–4. 10.1136/hrt.78.5.472
8.
AbramowitzYJilaihawiHChakravartyTMackMJMakkarRR. Mitral annulus calcification. J Am Coll Cardiol. (2015) 66:1934–41. 10.1016/j.jacc.2015.08.872
9.
RobertsWC. Morphologic features of the normal and abnormal mitral valve. Am J Cardiol. (1983) 51:1005–28. 10.1016/S0002-9149(83)80181-7
10.
ElmariahSBudoffMJDelaneyJAHamiraniYEngJFusterVet al. Risk factors associated with the incidence and progression of mitral annulus calcification: the multi-ethnic study of atherosclerosis. Am Heart J. (2013) 166:904–12. 10.1016/j.ahj.2013.08.015
11.
MasseraDTrivieriMGAndrewsJPMSartoriSAbgralRChapmanARet al. Disease activity in mitral annular calcification. Circ Cardiovasc Imaging. (2019) 12:e008513. 10.1161/CIRCIMAGING.118.008513
12.
LangRMBadanoLPMor-AviVAfilaloJArmstrongAErnandeLet al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. (2015) 16:233–70. 10.1093/ehjci/jev014
13.
KizerJRWiebersDOWhisnantJPGallowayJMWeltyTKLeeETet al. Mitral annular calcification, aortic valve sclerosis, and incident stroke in adults free of clinical cardiovascular disease: the Strong Heart Study. Stroke. (2005) 36:2533–7. 10.1161/01.STR.0000190005.09442.ad
14.
JassalDSTamJWBhagirathKMGabouryISochowskiRADumesnilJGet al. Association of mitral annular calcification and aortic valve morphology: a substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study. Eur Heart J. (2008) 29:1542–7. 10.1093/eurheartj/ehn172
15.
AkramMRChanTMcAuliffeSChenzbraunA. Non-rheumatic annular mitral stenosis: prevalence and characteristics. Eur J Echocardiogr. (2009) 10:103–5. 10.1093/ejechocard/jen179
16.
OttoCMNishimuraRABonowROCarabelloBAErwinJP 3rdGentileFet al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. (2021) 143:e72–e227. 10.1161/CIR.0000000000000932
17.
BenjaminEJPlehnJFD'AgostinoRBBelangerAJComaiKFullerDLet al. Mitral annular calcification and the risk of stroke in an elderly cohort. N Engl J Med. (1992) 327:374–9. 10.1056/NEJM199208063270602
18.
FoxCSPariseHVasanRSLevyDO'DonnellCJD'AgostinoRBet al. Mitral annular calcification is a predictor for incident atrial fibrillation. Atherosclerosis. (2004) 173:291–4. 10.1016/j.atherosclerosis.2003.12.018
19.
O'NealWTEfirdJTNazarianSAlonsoAMichosEDSzkloMet al. Mitral annular calcification progression and the risk of atrial fibrillation: results from MESA. Eur Heart J Cardiovasc Imaging. (2018) 19:279–84. 10.1093/ehjci/jex093
20.
O'NealWTEfirdJTNazarianSAlonsoAHeckbertSRSolimanEZ. Mitral annular calcification and incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis. Europace. (2015) 17:358–63. 10.1093/europace/euu265
21.
ManJJBeckmanJAJaffeIZ. Sex as a biological variable in atherosclerosis. Circ Res. (2020) 126:1297–319. 10.1161/CIRCRESAHA.120.315930
22.
MendelsohnMEKarasRH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. (1999) 340:1801–11. 10.1056/NEJM199906103402306
23.
SugiharaNMatsuzakiM. The influence of severe bone loss on mitral annular calcification in postmenopausal osteoporosis of elderly Japanese women. Jpn Circ J. (1993) 57:14–26. 10.1253/jcj.57.14
24.
HakAEPolsHAvanHemert AMHofmanAWittemanJC. Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Thromb Vasc Biol. (2000) 20:1926–31. 10.1161/01.ATV.20.8.1926
25.
CarrollJDCarrollEPFeldmanTWardDMLangRMMcGaugheyDet al. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation. (1992) 86:1099–107. 10.1161/01.CIR.86.4.1099
26.
KrumholzHMLarsonMLevyD. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol. (1993) 72:310–3. 10.1016/0002-9149(93)90678-6
27.
EleidMFFoleyTASaidSMPislaruSVRihalCS. Severe mitral annular calcification: multimodality imaging for therapeutic strategies and interventions. JACC Cardiovasc Imaging. (2016) 9:1318–37. 10.1016/j.jcmg.2016.09.001
28.
SudKAgarwalSParasharARazaMQPatelKMinDet al. Degenerative mitral stenosis: unmet need for percutaneous interventions. Circulation. (2016) 133:1594–604. 10.1161/CIRCULATIONAHA.115.020185
29.
TyagiGDangPPascaIPatelRPaiRG. Progression of degenerative mitral stenosis: insights from a cohort of 254 patients. J Heart Valve Dis. (2014) 23:707–12. Available online at: https://www.icr-heart.com/?cid=3943&g=3
30.
PascaIDangPTyagiGPaiRG. Survival in patients with degenerative mitral stenosis: results from a large retrospective cohort study. J Am Soc Echocardiogr. (2016) 29:461–9. 10.1016/j.echo.2015.12.012
31.
BertrandPBChurchillTWYucelENamasivayamMBernardSNagataYet al. Prognostic importance of the transmitral pressure gradient in mitral annular calcification with associated mitral valve dysfunction. Eur Heart J. (2020) 41:4321–8. 10.1093/eurheartj/ehaa819
Summary
Keywords
mitral annular calcification (MAC), sex, echocardiography, mitral stenosis (MS), mitral valve (MV)
Citation
Seo J, Jeong H, Cho I, Hong G-R, Ha J-W and Shim CY (2021) Sex Differences in Mitral Annular Calcification and the Clinical Implications. Front. Cardiovasc. Med. 8:736040. doi: 10.3389/fcvm.2021.736040
Received
04 July 2021
Accepted
22 September 2021
Published
14 October 2021
Volume
8 - 2021
Edited by
Adrian Chester, The Magdi Yacoub Institute, United Kingdom
Reviewed by
Gregg Pressman, Einstein Healthcare Network, United States; Mani Vannan, Piedmont Heart Institute, United States
Updates
Copyright
© 2021 Seo, Jeong, Cho, Hong, Ha and Shim.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Chi Young Shim cysprs@yuhs.ac
This article was submitted to Heart Valve Disease, a section of the journal Frontiers in Cardiovascular Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.